Pfizer discontinues development of dilated cardiomyopathy drug emprumapimod

Pfizer conducted an interim futility analysis of their global Phase III trial, REALM-DCM, to test the efficacy and safety of emprumapimod (PF-07265803) in patients with dilated cardiomyopathy (DCM) due to a lamin gene mutation. Based on this analysis, Pfizer found that the trial is unlikely to meet its primary endpoint, leading the company to cease the development of emprumapimod.